



June 2, 2025

Monarch Labs, LLC
Attention: James Kuo
17875 Sky Park Circle, Suite K
Irvine, CA 92614

Re: BK251209 (Formerly K033391)
Trade/Device Name: Medical Maggots
Regulation Number: Pre-Amendment
Regulation Name: Pre-Amendment
Regulatory Class: Unclassified
Product Code: NQK

Dear James Kuo:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated January 12, 2004. Specifically, FDA is updating this SE Letter because FDA has assigned your submission a new submission tracking number.

Please update the registration and listing of the device within the FURLS Device Registration and Listing Module according to <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/ucm053185.htm>.

For more information, please refer to the Federal Register Notice *Transfer of Regulatory Responsibility From the Center for Devices and Radiological Health to the Center for Biologics Evaluation and Research; Medical Maggots and Medicinal Leeches* (89 FR 106521, available at <https://www.federalregister.gov/documents/2024/12/30/2024-31266/transfer-of-regulatory-responsibility-from-the-center-for-devices-and-radiological-health-to-the>).

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact the Regulatory Project Manager, Rachel Blasdell, by email at Rachel.Blasdell@fda.hhs.gov.

Sincerely,

Steven S. Oh, PhD
Deputy Director
Office of Cellular Therapy and Human Tissue
Office of Therapeutic Products
Center for Biologics Evaluation and Research

Enclosure



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JAN 12 2004

Mr. Ronald A. Sherman
36 Urey Court
Irvine, California 92612

Re: K033391
Trade/Device Name: Medical Maggots
Regulatory Class: Unclassified
Product Code: NQK
Dated: October 16, 2003
Received: October 23, 2003

Dear Mr. Sherman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmanmain.html>

Sincerely yours,

Miriam C. Probst
for Celia M. Witten, Ph.D., M.D.

Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): **K033391**

Device Name: **Medical Maggots**

Indications For Use:

For debriding non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post surgical wounds.

Prescription Use **X**
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Miriam C. Provert
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

Page 1 of 1

510(k) Number **K033391**